India's Sun Pharmaceuticals has sent a letter to the board of directors of Israel's Taro Pharmaceutical Industries, requesting transparency regarding its reasons for dropping out of a merger of the two firms (Marketletter June 9).
Sun believes a press release from Taro on May 28 indicates the Israeli firm intends to sell its Irish subsidiary to a group of local investors. Taro claimed Sun prohibited the sale of Taro Ireland, despite rising operating costs, that Taro says are a detriment to shareholder value.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze